Important Announcements

Nondiscrimination Statement Update

Boston Medical Center Health System complies with applicable Federal civil rights laws and does not discriminate on the basis of age, race, color, national origin (including limited English proficiency and primary language), religion, culture, physical or mental disabilities, socioeconomic status, sex, sexual orientation and gender identity and/or expression. BMCHS provides free aids and services to people with disabilities and free language services to people whose primary language is not English.

To see our full nondiscrimination statement, click here.

Campus Construction Update

Starting September 14, we’re closing the Menino building lobby entrance. This, along with the ongoing Yawkey building entrance closure, will help us bring you an even better campus experience that matches the exceptional care you've come to expect. Please enter the Menino and Yawkey buildings through the Moakley building, and make sure to leave extra time to get to your appointment. Thank you for your patience. 

Click here to learn more about our campus redesign. 

TRA 2P – TIMI 50

Select your language:

TRA 2P – TIMI 50: Trial to Assess the Effects of SCH 530348 in Preventing Heart Attack and Stroke in Patients With Atherosclerosis

Sponsor: Schering Plough

Investigators: Carlos Kase MD (principal), Viken Babikian MD, Jose Romero MD

Trial results available here

This was a large clinical trial (with 26,449 patients) that evaluated whether the addition of SCH 530348 (Vorapaxar) to existing standard of care will yield additional benefit in prevention of heart attacks and strokes. In stable patients with a history of atherothrombosis, study results showed decreased deaths from cardiovascular disease, MI and stroke incidence and increased moderate and severe bleeding when added to standard of care. It appears to reduce recurrent atherothrombosis, caution is patient selection is needed due to increase bleeding.